Our team has also recently reported that upregulation of α-tubulin (TUB), vimentin (VIM) and detyrosinated α-tubulin (GLU) in CTCs derived from breast cancer patients could be deployed as useful biomarkers to identify cancer cells with an aggressive phenotype. This evidence concerns the gene TUB and breast cancer.